OBJECTIVES The aim of this study was to examine the frequency and clinical impact of different cessation patterns of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents among patients with and those without diabetes mellitus (DM).
has reduced the rate of target lesion failure and repeat revascularization in patients with DM, incidence continues to be higher than in patients without DM (5,6).
Current clinical practice guidelines on the management of patients undergoing PCI recommend 6-to 12-month dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor following DES implantation unless patients are at high risk for bleeding (7) .
There is no specific indication for DAPT duration in patients with DM. Therefore, the most appropriate DAPT regimen for patients with DM remains a subject of debate. Recent observational studies have suggested that short-term DAPT could be safe and effective in patients with DM with either stable coronary artery disease or low-risk acute coronary syndromes (ACS) after the implantation of second-generation DES (8) (9) (10) . However, these results might not apply to high-risk patients with DM and ACS or to patients receiving bare-metal stents or first-generation DES.
Cessation of DAPT treatment after PCI in the general population is critical, because it increases the risk for adverse clinical outcomes. In particular, results Importantly, DAPT cessation events were not mutually exclusive, and patients could experience more than 1 DAPT cessation mode (discontinuation, interruption, or disruption) during the investigation time.
In that case, the DAPT cessation variable was adjudicated according to the following hierarchical order: disruption had priority over interruption, which in turn had priority over recommended discontinuation.
Additionally, DAPT cessation longer than 30 days did not preclude the reinclusion of patients subsequently resuming DAPT. Values are n (%) or mean AE SD.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease including myocardial infarction, PCI, and CABG; CVA ¼ cerebrovascular accident; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular disease; TIA ¼ transient ischemic attack. at 1 year and 50.1% vs. 55.4% at 2 years; p < 0.01) ( Figure 2) . There was no significant difference in either DAPT interruption or DAPT disruption between groups, although interruption tended to be more frequent in patients with DM at 1 and 2 years after index PCI (5.0% vs. 3.8% at 1 year and 11.4% vs. 9.5% at 2 years; p ¼ 0.053) ( Figure 2) . Because DAPT discontinuation emerged as the only cessation mode to differ between the study groups, next, we investigated patterns of DAPT discontinuation in relevant subsets of the study population. We found no difference in the pattern of DAPT discontinuation according to antidiabetic treatment, oral medication or insulin ( Figure 3A) .
However, a subanalysis by clinical presentation showed a lower rate of DAPT discontinuation at any time point in patients presenting with ACS compared with stable CAD counterparts in both patients with and those without DM. Interestingly, the difference in the incidence of discontinuation at 2 years between those presenting with stable CAD and those with ACS was 3 times higher in patients with DM than in those without DM ( Figure 3B) Results were consistent over time at both 1 and 2 years, whereas at 30 days after index PCI, only allcause mortality and cardiac death were significantly higher among patients with DM (data not shown).
There was no difference in bleeding rates during the 2 years of follow-up according to TIMI and Bleeding Academic Research Consortium criteria ( Table 3) . 
DISCUSSION
In the present analysis involving more than 4,000 realworld patients undergoing PCI predominantly with second-generation DES, we report the following key findings: 1) the presence of DM was associated with increased thrombotic but not bleeding events over 2 years; 2) DAPT cessation was less frequent among patients with DM, which was attributable primarily to differences in rates of physician-guided discontinuation between groups; 3) cardiovascular risk after DAPT cessation because of physician-recommended discontinuation or temporary interruption was not increased among patients with versus without DM; and 4) conversely, when DAPT was disrupted because of bleeding or noncompliance, the risk for all cardiovascular adverse events significantly increased in a uniform manner irrespective of diabetic status. In aggregate, these findings suggest that physicians are reluctant to recommend discontinuation of antiplatelet therapy among patients with DM, a practice pattern that is concordant with the prothrombotic nature of such patients. We also demonstrate that DM is not a modifier of risk subsequent to DAPT cessation irrespective of underlying mode.
Overall, the cumulative rate of DAPT cessation was lower among patients with DM, a finding that was driven primarily by differences in the rates of physician-recommended discontinuation. In contrast, the incidence of temporary DAPT interruption did not differ significantly between groups.
Previous studies have shown that DM is an independent predictor of uninterrupted DAPT after PCI, together with unstable presentation, prior MI, left main coronary PCI, and multivessel coronary disease (16, 17) . Our results extend these earlier observations by suggesting that in a real-world context, physicians are less likely to stop DAPT among those with DM, a behavior that might reflect concerns surrounding Values are n (%).
BARC ¼ Bleeding Academic Research Consortium; MACE ¼ major adverse cardiac event(s) (cardiac death, myocardial infarction, clinically indicated target lesion revascularization, or definite or probable stent thrombosis); MACE 2 ¼ major adverse cardiac event(s) 2 (cardiac death, myocardial infarction, or definite or probable stent thrombosis); TIMI ¼ Thrombolysis In Myocardial Infarction. patients. This practice pattern is consistent with emerging risk algorithms highlighting the importance of DM as an independent correlate of thrombotic, but not bleeding, events after PCI, thereby reinforcing the need for longer or more potent platelet inhibition in such patients (18, 19) . Results from a subanalysis of the DAPT trial, for example, suggest that prolonging DAPT might reduce the risk for outcomes in patients with DM, whereas the benefit appears to be attenu- In contrast to our findings with respect to physician-guided discontinuation, we observed no differences between groups in rates of temporary interruption because of surgical procedures or disruption arising from bleeding or noncompliance. These results suggest that the presence of DM does not play a significant role in clinical decision making with respect to suspension of antiplatelet therapy when prompted by external conditions, such as bleeding. As rates of bleeding were similar between patients with and those without DM, the lack of any differences in disruption is somewhat expected.
However, the comparable rates of interruption between groups may be less intuitive given the wellestablished links between DM and increased platelet reactivity, coupled with the procoagulant milieu that characterizes the post-operative state (22, 23) . Several 
